Background: Multiple sclerosis (MS) is a long-term autoimmune inflammatory disorder that affects the central nervous system leading to neurodegeneration, and can involve a variety of symptoms. These symptoms can include fatigue, anxiety, depression, and cognitive decline, which may be silent. The objective of this study was to explore changes in brain iron deposition in people with relapsing-remitting MS (pw-RRMS) compared to healthy controls (HCs), with a particular focus on regions of fear circuit. Additionally, the study aimed to evaluate relationship between iron deposition in these areas and clinical measurements. Methods: Pw-RRMS and HCs participants underwent brain MRI scans using quantitative susceptibility mapping (QSM) to assess iron deposition in the fear circuit between the two groups. The study analyzed correlations between brain susceptibility changes and clinical measurements. Results: We recruited 35 pw-RRMS (mean age = 46.7 ± 11 years; median EDSS = 2.5) and 18 HCs (mean age = 40.6 ± 17.8 years). Our research revealed significant increases in QSM signals relating to iron deposition in pw-RRMS compared to HCs, whole fear circuit (β = 5.82, p < 0.001), caudate (β = 21.48, p < 0.001), and putamen (β = 17.53, p = 0.03), showing the greatest difference. The whole fear circuit and particularly the caudate are strongly associated with fatigue in pw-RRMS. QSM values in the anterior cingulate cortex significantly differed between pw-RRMS with normal and abnormal depression scores (p = 0.007). Conclusions: These results strengthen the relationship between increased iron deposition in fear circuit regions and specific silent symptoms in pw-RRMS. However, further studies are required to confirm these findings and clarify the implications of iron accumulation in MS pathophysiology.
ArmJRibbonsKLechner-ScottJ, et al.Evaluation of MS related central fatigue using MR neuroimaging methods: scoping review. J Neurol Sci2019; 400: 52–71.
4.
LakinLDavisBEBinnsCC, et al.Comprehensive approach to management of multiple sclerosis: addressing invisible symptoms—a narrative review. Neurol Ther2021; 10(1): 75–98.
5.
PinterDEnzingerC. Neuroimaging and fatigue. In: PennerI-K (ed) Fatigue in multiple sclerosis: background, clinic, diagnostic, therapy. Cham, Switzerland: Springer International Publishing, 2023, pp. 123–134.
6.
PalotaiMMikeACavallariM, et al.Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. Mult Scler2018; 24(8): 1105–1114.
7.
AlshehriAKoussisNAl-IedaniO, et al.Improvement of the thalamocortical white matter network in people with stable treated relapsing-remitting multiple sclerosis over time. NMR Biomed2024; 37: e5119.
8.
EngströmMFlensnerGLandtblomAM, et al.Thalamo‐striato‐cortical determinants to fatigue in multiple sclerosis. Brain Behav2013; 3(6): 715–728.
9.
HogestolEANygaardGOAlnæsD, et al.Symptoms of fatigue and depression is reflected in altered default mode network connectivity in multiple sclerosis. PLoS One2019; 14(4): e0210375.
10.
EllwardtEMuthuramanMGonzalez-EscamillaG, et al.Network alterations underlying anxiety symptoms in early multiple sclerosis. J Neuroinflammation2022; 19(1): 119.
11.
StephensonENathooNMahjoubY, et al.Iron in multiple sclerosis: roles in neurodegeneration and repair. Nat Rev Neurol2014; 10(8): 459–468.
12.
HametnerSWimmerIHaiderL, et al.Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol2013; 74(6): 848–861.
13.
ZierfussBWangZJacksonAN, et al.Iron in multiple sclerosis – neuropathology, immunology, and real-world considerations. Mult Scler Relat Disord2023; 78: 104934.
14.
HuangWSweeneyEMKaunznerUW, et al.Quantitative susceptibility mapping versus phase imaging to identify multiple sclerosis iron rim lesions with demyelination. J Neuroimaging2022; 32(4): 667–675.
15.
HarrisonDMLiXLiuH, et al.Lesion heterogeneity on high-field susceptibility MRI is associated with multiple sclerosis severity. AJNR Am J Neuroradiol2016; 37(8): 1447–1453.
16.
AbsintaMSatiPMasuzzoF, et al.Association of chronic active multiple sclerosis lesions with disability in vivo. JAMA Neurol2019; 76(12): 1474–1483.
17.
NeemaMAroraAHealyBC, et al.Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging2009; 19(1): 3–8.
18.
MarekRStrobelCBredyTW, et al.The amygdala and medial prefrontal cortex: partners in the fear circuit. J Physiol2013; 591(10): 2381–2391.
19.
TovotePFadokJPLüthiA. Neuronal circuits for fear and anxiety. Nat Rev Neurosci2015; 16(6): 317–331.
20.
PenzoMARobertVTucciaroneJ, et al.The paraventricular thalamus controls a central amygdala fear circuit. Nature2015; 519(7544): 455–459.
21.
LiHPenzoMATaniguchiH, et al.Experience-dependent modification of a central amygdala fear circuit. Nat Neurosci2013; 16(3): 332–339.
22.
ChenKZhangLMaoH, et al.The impact of iron deposition on the fear circuit of the brain in patients with Parkinson's disease and anxiety. Front Aging Neurosci2023; 15: 1116516.
23.
CareyGLopesRViardR, et al.Anxiety in Parkinson's disease is associated with changes in the brain fear circuit. Parkinsonism Relat Disorders2020; 80: 89–97.
24.
CareyGGörmezoğluMde JongJJA, et al.Neuroimaging of anxiety in Parkinson's disease: a systematic review. Mov Disord2021; 36(2): 327–339.
25.
PerepezkoKNaazFWagandtC, et al.Anxiety in Parkinson's disease: a systematic review of neuroimaging studies. J Neuropsychiatry Clin Neurosci2021; 33(4): 280–294.
26.
ChenYWuYMuJ, et al.Abnormal fear circuits activities correlated to physical symptoms in somatic anxiety patients. J Affect Disord2020; 274: 54–58.
27.
ShinLMLiberzonI. The neurocircuitry of fear, stress, and anxiety disorders. Focus2011; 9(3): 311–334.
28.
HartleyCAPhelpsEA. Changing fear: the neurocircuitry of emotion regulation. Neuropsychopharmacology2010; 35(1): 136–146.
29.
ReevesJA, et al. Paramagnetic rim lesions are associated with greater incidence of relapse and worse cognitive recovery following relapse. Mult Scler. 2023; 29(8): 1033–1038.
30.
CoffmanCHWhiteRSubramanianK, et al.Quantitative susceptibility mapping of both ring and non-ring white matter lesions in relapsing remitting multiple sclerosis. Magn Reson Imaging2022; 91: 45–51.
31.
ThompsonAJBanwellBLBarkhofF, et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
32.
PolmanCHReingoldSCBanwellB, et al.Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
33.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
34.
KruppLBLaRoccaNGMuir-NashJ, et al.The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol1989; 46(10): 1121–1123.
35.
KruppLBCoylePKDoscherC, et al.Fatigue therapy in multiple sclerosis: results of a double‐blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995; 45(11): 1956–1961.
36.
ZigmondASSnaithRP. The hospital anxiety and depression scale. Acta Psychiatr Scand1983; 67(6): 361–370.
37.
HonarmandKFeinsteinA. Validation of the hospital anxiety and depression scale for use with multiple sclerosis patients. Mult Scler2009; 15(12): 1518–1524.
38.
GiordanoAGranellaFLugaresiA, et al.Anxiety and depression in multiple sclerosis patients around diagnosis. J Neurol Sci2011; 307(1): 86–91.
39.
WuBLiWGuidonA, et al.Whole brain susceptibility mapping using compressed sensing. Magn Reson Med2012; 67(1): 137–147.
40.
LiWWuBLiuC. STI Suite: a software package for quantitative susceptibility imaging. Proc Intl Soc Mg Reson Med. 2014; 22: 3265.
41.
Dal-BiancoAGrabnerGKronnerwetterC, et al.Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI. Brain2021; 144(3): 833–847.
42.
Dal-BiancoAGrabnerGKronnerwetterC, et al.Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol2017; 133(1): 25–42.
43.
AlTokhisAIAlOtaibiAMFelmbanGA, et al.Iron rims as an imaging biomarker in ms: a systematic mapping review. Diagnostics2020; 10(11): 968.
44.
ZhangHNguyenTDZhangJ, et al.QSMRim-Net: imbalance-aware learning for identification of chronic active multiple sclerosis lesions on quantitative susceptibility maps. Neuroimage Clin2022; 34: 102979.
45.
StuberCPittDWangY. Iron in multiple sclerosis and its noninvasive imaging with quantitative susceptibility mapping. Int J Mol Sci2016; 17(1): 100.
46.
SunHWalshAJLebelRM, et al.Validation of quantitative susceptibility mapping with Perls' iron staining for subcortical gray matter. Neuroimage2015; 105: 486–492.
47.
PalotaiMGuttmannCRG. Brain anatomical correlates of fatigue in multiple sclerosis. Mult Scler2020; 26(7): 751–764.
48.
PalotaiMNazeriACavallariM, et al.History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep2019; 9(1): 14781.
49.
PaulF. Pathophysiology and differentiation from other symptoms and diseasess. In: Fatigue in multiple sclerosis: background, clinic, diagnostic, therapy. Cham, Switzerland: Springer, 2023, pp. 27–39.
50.
HagemeierJZivadinovRDwyerMG, et al.Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain. Neuroimage Clin2018; 18: 1007–1016.
51.
HamdyEGaleelAARamadanI, et al.Iron deposition in multiple sclerosis: overall load or distribution alteration?Eur Radiol Exp2022; 6(1): 49.
52.
ChawlaSKisterISinneckerT, et al.Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. PLoS One2018; 13(9): e0202918.
53.
ZivadinovRTavazziEBergslandN, et al.Brain iron at quantitative MRI is associated with disability in multiple sclerosis. Radiology2018; 289(2): 487–496.
54.
ZhangWZhouYLiQ, et al.Brain iron deposits in thalamus is an independent factor for depressive symptoms based on quantitative susceptibility mapping in an older adults community population. Front Psychiatr2019; 10: 734.
55.
BatistaSZivadinovRHoogsM, et al.Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol2012; 259: 139–146.
56.
FujiwaraEKmechJACobzasD, et al.Cognitive implications of deep gray matter iron in multiple sclerosis. AJNR Am J Neuroradiol2017; 38(5): 942–948.
57.
SchweserFHagemeierJDwyerMG, et al.Decreasing brain iron in multiple sclerosis: the difference between concentration and content in iron MRI. Hum Brain Mapp2021; 42(5): 1463–1474.
58.
AdamP, et al. Deep gray matter iron content in neuromyelitis optica and multiple sclerosis. BioMed Res Int. 2020; 1: 6492786.
59.
SchweserFRaffaini Duarte MartinsALHagemeierJ, et al.Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: a proposed mechanistic relationship between inflammation and oligodendrocyte vitality. Neuroimage2018; 167: 438–452.
60.
ElkadyAMCobzasDSunH, et al.Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls. Mult Scler Relat Disord2019; 33: 107–115.
61.
HaiderLSimeonidouCSteinbergerG, et al.Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron. J Neurol Neurosurg Psychiatry2014; 85(12): 1386–1395.
62.
WangZZengYNYangP, et al.Axonal iron transport in the brain modulates anxiety-related behaviors. Nat Chem Biol2019; 15(12): 1214–1222.
63.
XuXWangQZhangM. Age, gender, and hemispheric differences in iron deposition in the human brain: an in vivo MRI study. Neuroimage2008; 40(1): 35–42.
64.
DuLZhaoZCuiA, et al.Increased iron deposition on brain quantitative susceptibility mapping correlates with decreased cognitive function in alzheimer's disease. ACS Chem Neurosci2018; 9(7): 1849–1857.
65.
Acosta-CabroneroJWilliamsGBCardenas-BlancoA, et al.In vivo quantitative susceptibility mapping (QSM) in Alzheimer's disease. PLoS One2013; 8(11): e81093.
66.
BilgicBCostagliMChanKSQSM Consensus Organization Committee, et al. Recommended implementation of quantitative susceptibility mapping for clinical research in the brain: a consensus of the ISMRM electro‐magnetic tissue properties study group. Magn Reson Med. 2024; 91(5): 1834–1862.
67.
GongN-JWongCSHuiES, et al.Hemisphere, gender and age-related effects on iron deposition in deep gray matter revealed by quantitative susceptibility mapping. NMR Biomed2015; 28(10): 1267–1274.
68.
YarraguntlaKSeraji-BozorgzadNLichtman-MikolS, et al.Multiple sclerosis fatigue: a longitudinal structural MRI and diffusion tensor imaging study. J Neuroimaging2018; 28(6): 650–655.
69.
GobbiCRoccaMAPaganiE, et al.Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Mult Scler2014; 20(12): 1633–1640.
70.
ZorzonMde MasiRNasuelliD, et al.Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol2001; 248: 416–421.
71.
HillyerASharmaMKuurstraA, et al.Association between limbic system lesions and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord2023; 79: 105021.
72.
ChalahMAKauvPCréangeA, et al.Neurophysiological, radiological and neuropsychological evaluation of fatigue in multiple sclerosis. Mult Scler Relat Disord2019; 28: 145–152.
73.
ElkadyAMCobzasDSunH, et al.Five year iron changes in relapsing-remitting multiple sclerosis deep gray matter compared to healthy controls. Mult Scler Relat Disord2019; 33: 107–115.
74.
WangFZhangMLiY, et al.Alterations in brain iron deposition with progression of late-life depression measured by magnetic resonance imaging (MRI)-based quantitative susceptibility mapping. Quant Imag Med Surg2022; 12(7): 3873–3888.
75.
YaoSZhongYXuY, et al.Quantitative susceptibility mapping reveals an association between brain iron load and depression severity. Front Hum Neurosci2017; 11: 442.
76.
NigroSPassamontiLRiccelliR, et al.Structural ‘connectomic’alterations in the limbic system of multiple sclerosis patients with major depression. Mult Scler2015; 21(8): 1003–1012.
77.
PassamontiLCerasaALiguoriM, et al.Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain2009; 132(12): 3380–3391.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
